SkinMedica®, by the makers of BOTOX® Cosmetic (onabotulinumtoxinA) launches the first and only product to use a proprietary complex of five forms of Hyaluronic Acid (HA) and Hydra Collagen, plus Advanced VITISENSCE® Technology for deeper hydrationIRVINE, Calif., Aug. 27, 2024 /PRNewswire/ -- For 25 years, SkinMedica® has been at the forefront of science-based skincare solutions, and today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of its next generation hydration product: Ski ...

These stocks are the A-team for income investors.Which income investors want to buy stocks with dividends likely to decline and iffy businesses? None. Instead, income investors want practically unstoppable dividend stocks.Three Motley Fool contributors think they've identified healthcare stocks that fit the bill. Here's why they picked Abbott Laboratories (ABT 0.53%), Amgen (AMGN 1.32%), and AbbVie (ABBV 0.60%).A Dividend King with a diverse business to buy and hold for yearsDavid Jagielski (Abbott Laborato ...

29 April 2024, Rhineland-Palatinate, Ludwigshafen: Photo: Uwe Anspach/dpa (Photo by Uwe ... [+] Anspach/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesWe believe that the pharmaceuticals giant Merck (NYSE: MRK) is currently a better pick over its peer, AbbVie stock. MRK stock trades at 14x forward earnings, versus 20x for ABBV. We think this gap in valuation will narrow in favor of Merck in the coming years, given its superior revenue growth and profitability. There is more to the co ...

AbbVie (ABBV) and partner, Genmab (GMAB) , announced that the European Commission has granted conditional marketing authorization for the expanded use of Tepkinly (epcoritamab) to treat relapsed or refractory follicular lymphoma (FL) after two or more therapies. R/R FL is a particularly difficult-to-treat form of cancer, especially in later lines of therapy, for which there is currently no standard of care treatment.The encouraging regulatory update follows the positive opinion that was adopted by the advis ...

TEPKINLY (epcoritamab) is the first and only subcutaneous bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) follicular lymphoma (FL) and R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of prior therapyFL is an incurable form of non-Hodgkin's lymphoma (NHL), with about 13,000 estimated cases in Western Europe alone each year1NORTH CHICAGO, Ill., Aug. 19, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that ...

These stocks dividends continue to flow and grow.What do income investors like better than a stock that pays a juicy dividend yield? The answer is easy: A stock with a juicy dividend yield that's likely to grow its dividend payout over time.Such stocks aren't as hard to find as some might think. Here are three high-yield dividend stocks to buy now that have increased their dividends for 25 years or more.1. AbbVieAbbVie's (ABBV 0.26%) forward dividend yield of over 3.2% isn't as high as it was earlier this y ...

This list of top-selling drugs could look drastically different in a few years.You might think that if a drugmaker has a top-selling drug, it would be a lock to be a top-performing stock and a no-brainer buy. That may be true in some cases. In others, it can be a source of risk as investors grow concerned about what a company's growth opportunities will look like after the relevant patent expires, especially when the drug accounts for a significant chunk of the company's sales.The three top-selling drugs in ...

These stocks all pay more than 3%, and they have been regularly increasing their payouts in recent years.If you're a retiree looking to make the most of your nest egg, putting money into dividend stocks can be a great way to do that. You can help maximize the recurring income you earn by investing in dividend growth stocks, which have strong track records for raising their payouts. Dividend payments are never a guarantee, but companies with strong financials which prioritize growing their payouts can be ide ...

Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future. Many of these stocks have fallen out of fashion in the tech-fueled AI revolution. But in the last month, many of these stocks are increasing as investors feel more bullish about the economy.  Investors who reinvest those dividends have the opportunity to increase their total return on th ...

Everything looked like it was coming undone last week. As recession fears gripped the market, the S&P 500 tumbled 3% in a single day. The Nasdaq 100 lost more than 1,000 points at one point, its worst loss ever, before regaining some of the lost ground.Although the situation turned markedly better by Tuesday and continued improving as the week progressed, the whipsaw event still has investors cautious. Wild swing trades can often signal a new, worse crash is coming. That’s why it’s important to prepare for ...